Drug Profile
Dexmecamylamine - Atacama Therapeutics
Alternative Names: AT-5214; Dexmecamylamine hydrochloride; NIH-11008; S-mecamylamine; TC-5214Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of South Florida Research Foundation
- Developer AstraZeneca; Atacama Therapeutics; Targacept
- Class Antidepressants; Norbornanes; Skin disorder therapies; Small molecules
- Mechanism of Action Alpha3beta4 nicotinic receptor antagonists; Alpha4beta2 nicotinic receptor antagonists; Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperhidrosis
- Discontinued Hypertension; Major depressive disorder; Overactive bladder; Resistant hypertension
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 03 Sep 2021 Phase II development for Hyperhidrosis is ongoing in USA (Atacama Therapeutics pipeline, September 2021) (NCT04263623)
- 20 Jul 2021 Atacama Therapeutics completed enrolment in the phase II trial for Hyperhidrosis (Treatment-naive) in USA (PO) (NCT04263623)